Alcobra Pharma, an emerging company focused on the
development of new medications to help patients with cognitive disorders, has
announced financial results for the fourth quarter and fiscal year ended
December 31, 2014, and provided a business update.
The company reported ($0.50) EPS for the quarter, beating the Thomson
Reuters consensus estimate of ($0.57) by $0.07. They set a 'buy' rating and a
$10.00 price target on the stock. Analysts at Zacks downgraded shares of
Alcobra from an 'outperform' rating to a 'neutral' rating and set a $3.90 price
target on the stock in a research note on Wednesday, November 26th.
Finally, analysts at Aegis downgraded shares of Alcobra from a 'buy' rating
to a "hold" rating in a research note on Monday, November 17th. Five equities
research analysts have rated the stock with a hold rating and four have given a
buy rating to the company's stock. The company currently has an average rating
of 'Hold' and a consensus target price of $17.56.